[Form 4/A] Processa Pharmaceuticals, Inc. Amended Insider Trading Activity

Rhea-AI Filing Summary

Processa Pharmaceuticals, Inc. (PCSA) filed an amended Form 4 to correct an earlier filing. The amendment states the prior Form 4 was filed in error and retracts that prior report. The filing lists David Young (President, Research & Development and director) as the reporting person and shows a transaction date of 07/24/2025. The Table I entries indicate a disposition of 217,332 common shares and beneficial ownership reported as 30,985 shares direct plus indirect holdings: 10,786 shares via the Young-Plaisance Revocable Trust, 18,544 shares via CorLyst, LLC. The amendment is signed by David Young via attorney-in-fact John J. Wolfel on 09/18/2025.

Positive

• Amendment retracts prior erroneous filing, restoring accuracy to the public insider reporting record
• Detailed beneficial ownership breakdown provided (direct and indirect holdings) for clearer transparency

Negative

• Prior Form 4 was filed in error, which may have temporarily caused inaccurate public reporting
• Large disposition of 217,332 shares is recorded (no additional context on price or reason provided)

Insights

Financial Analyst

TL;DR: Administrative correction of an insider report; no new economic detail provided beyond restated holdings.

The amended Form 4 retracts a previously filed Form 4 and restates the reporting person's holdings and a large disposition of 217,332 shares dated 07/24/2025. This filing itself does not provide new operational or financial performance data. For investors, the key facts are the reported disposition size and the clarified breakdown of direct and indirect beneficial ownership, which should be used to reconcile insider position data in ownership trackers and models.

Corporate Governance Expert

TL;DR: Correction improves public record accuracy; the amendment addresses a prior filing error without adding substantive new transactions.

The Form 4/A is an administrative amendment stating the earlier Form 4 was filed in error and retracting it. It confirms David Young's roles and provides the post-transaction ownership breakdown across direct and indirect holdings. From a governance perspective, timely and clear amendments are important for compliance and market transparency; this filing documents that compliance action.

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

1. Name and Address of Reporting Person^*

Young David

(Last) (First) (Middle)

C/O PROCESSA PHARMACEUTICALS, INC.

601 21ST STREET SUITE 300

(Street)

VERO BEACH FL 32960

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
Processa Pharmaceuticals, Inc. [ PCSA ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	Pres. Research & Development

3. Date of Earliest Transaction (Month/Day/Year)
07/24/2025

4. If Amendment, Date of Original Filed (Month/Day/Year)
07/28/2025

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock								217,332	D
Common Stock								30,985	I	By Young-Plaisance Revocable Trust
Common Stock								10,786	I	By Family Entities
Common Stock								18,544	I	By CorLyst, LLC

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

Remarks:

Amendment filed to retract the prior Form 4, which was filed in error.

	/s/ David Young by John J. Wolfel, as Attorney-in-Fact	09/18/2025
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What did the Form 4/A for Processa Pharmaceuticals (PCSA) change?

The Form 4/A states the prior Form 4 was filed in error and retracts that prior report, restating the reporting information.

Who is the reporting person on this Form 4/A for PCSA?

The reporting person is David Young, identified as President, Research & Development and a director.

What transaction is shown on the amended Form 4 dated 07/24/2025?

Table I shows a disposition of 217,332 common shares with post-transaction direct beneficial ownership of 30,985 shares and indirect holdings listed.

How are David Young's indirect holdings reported?

Indirect holdings are reported as 10,786 shares by the Young-Plaisance Revocable Trust and 18,544 shares by CorLyst, LLC.

When was the amendment signed and by whom?

The Form 4/A is signed by David Young via attorney-in-fact John J. Wolfel on 09/18/2025.